NO980592L - Nye opioidpeptider - Google Patents

Nye opioidpeptider

Info

Publication number
NO980592L
NO980592L NO980592A NO980592A NO980592L NO 980592 L NO980592 L NO 980592L NO 980592 A NO980592 A NO 980592A NO 980592 A NO980592 A NO 980592A NO 980592 L NO980592 L NO 980592L
Authority
NO
Norway
Prior art keywords
peptides
pain
opioid
preparation
opioid peptides
Prior art date
Application number
NO980592A
Other languages
English (en)
Norwegian (no)
Other versions
NO980592D0 (no
Inventor
Wuyi Wang
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502877A external-priority patent/SE9502877D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO980592D0 publication Critical patent/NO980592D0/no
Publication of NO980592L publication Critical patent/NO980592L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO980592A 1995-08-18 1998-02-11 Nye opioidpeptider NO980592L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9502877A SE9502877D0 (sv) 1995-08-18 1995-08-18 Novel opioid peptides
SE9503924A SE9503924D0 (sv) 1995-08-18 1995-11-07 Novel opioid peptides
PCT/SE1996/001011 WO1997007130A1 (en) 1995-08-18 1996-08-14 Novel opioid peptides

Publications (2)

Publication Number Publication Date
NO980592D0 NO980592D0 (no) 1998-02-11
NO980592L true NO980592L (no) 1998-02-11

Family

ID=26662362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980592A NO980592L (no) 1995-08-18 1998-02-11 Nye opioidpeptider

Country Status (27)

Country Link
US (1) US6337319B1 (cs)
EP (1) EP0845003B1 (cs)
JP (1) JPH11512086A (cs)
KR (1) KR19990037677A (cs)
CN (1) CN1200127A (cs)
AR (1) AR003475A1 (cs)
AT (1) ATE210148T1 (cs)
AU (1) AU711862B2 (cs)
BR (1) BR9610248A (cs)
CA (1) CA2229797A1 (cs)
CZ (1) CZ287299B6 (cs)
DE (1) DE69617699T2 (cs)
DK (1) DK0845003T3 (cs)
EE (1) EE9800048A (cs)
ES (1) ES2171224T3 (cs)
HU (1) HUP9901209A3 (cs)
IL (1) IL123258A (cs)
IS (1) IS4664A (cs)
NO (1) NO980592L (cs)
NZ (1) NZ315809A (cs)
PL (1) PL325113A1 (cs)
RU (1) RU2165432C2 (cs)
SE (1) SE9503924D0 (cs)
SK (1) SK282469B6 (cs)
TR (1) TR199800258T1 (cs)
TW (1) TW424095B (cs)
WO (1) WO1997007130A1 (cs)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032774A1 (en) * 1994-02-21 2003-02-13 Astrazeneca Ab Novel opioid peptides for the treatment of pain
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
SE9701718D0 (sv) * 1997-05-07 1997-05-07 Astra Ab Analgesic peptidomimetic compounds
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2001013938A1 (fr) * 1999-08-25 2001-03-01 Daiichi Fine Chemical Co., Ltd. Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
ATE496533T1 (de) 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
JP2002069059A (ja) * 2000-08-28 2002-03-08 Teikoku Seiyaku Co Ltd ピラジノン環を含む新規なオピオイドペプチド誘導体
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006132925A2 (en) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
EP1782819A1 (en) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
JP5244810B2 (ja) 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) * 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
BR112012001466A2 (pt) * 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102964279B (zh) * 2012-12-12 2014-05-07 中国药科大学 一类具有外周镇痛作用的κ阿片受体激动剂
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
DK0644772T3 (da) * 1992-11-12 2003-06-30 Sod Conseils Rech Applic Opioid-peptider
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Also Published As

Publication number Publication date
AR003475A1 (es) 1998-08-05
NO980592D0 (no) 1998-02-11
RU2165432C2 (ru) 2001-04-20
ES2171224T3 (es) 2002-09-01
DE69617699D1 (de) 2002-01-17
DE69617699T2 (de) 2003-08-07
SK282469B6 (sk) 2002-02-05
CA2229797A1 (en) 1997-02-27
AU711862B2 (en) 1999-10-21
CZ40198A3 (cs) 1998-08-12
HUP9901209A3 (en) 2000-12-28
ATE210148T1 (de) 2001-12-15
EP0845003A1 (en) 1998-06-03
DK0845003T3 (da) 2002-07-15
JPH11512086A (ja) 1999-10-19
IL123258A (en) 2003-03-12
CZ287299B6 (en) 2000-10-11
EP0845003B1 (en) 2001-12-05
TR199800258T1 (xx) 1998-05-21
NZ315809A (en) 1999-05-28
SK20398A3 (en) 1998-12-02
IL123258A0 (en) 1998-09-24
TW424095B (en) 2001-03-01
EE9800048A (et) 1998-08-17
HUP9901209A2 (hu) 1999-08-30
KR19990037677A (ko) 1999-05-25
CN1200127A (zh) 1998-11-25
BR9610248A (pt) 1999-07-06
AU6760096A (en) 1997-03-12
SE9503924D0 (sv) 1995-11-07
PL325113A1 (en) 1998-07-06
US6337319B1 (en) 2002-01-08
WO1997007130A1 (en) 1997-02-27
IS4664A (is) 1998-02-04

Similar Documents

Publication Publication Date Title
SE9503924D0 (sv) Novel opioid peptides
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
BR9506847A (pt) Composto composição farmacêutica uso de um composto processo para o tratamento da dor
BR0313388A (pt) Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
BG105434A (bg) Сертралинов орален концентрат
PT883401E (pt) Antagonista do receptor at1 para estimulacao da apoptose
GB9930077D0 (en) Medicaments
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
PT942729E (pt) Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse
GB9930085D0 (en) Medicaments
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
MY124089A (en) Use of cetirizine for preventing the onset of asthma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application